Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.

@article{Ansell2007PhaseIS,
  title={Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.},
  author={S. Ansell and S. Horwitz and A. Engert and K. Khan and T. Lin and R. Strair and T. Keler and R. Graziano and D. Blanset and M. Yellin and S. Fischkoff and A. Assad and P. Borchmann},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2007},
  volume={25 19},
  pages={
          2764-9
        }
}
  • S. Ansell, S. Horwitz, +10 authors P. Borchmann
  • Published 2007
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • PURPOSE MDX-060 is a human anti-CD30 immunoglobulin (Ig) G1kappa monoclonal antibody that inhibits growth of CD30-expressing tumor cells in preclinical models. To determine the safety, maximum-tolerated dose (MTD), and efficacy of MDX-060 in patients with relapsed or refractory CD30+ lymphomas, sequential phase I and II studies were performed. PATIENTS AND METHODS In the phase I portion, MDX-060 was administered intravenously at doses of 0.1, 1, 5, or 10 mg/kg weekly for 4 weeks to cohorts of… CONTINUE READING
    232 Citations

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    RATIONALE: Monoclonal antibodies such as MDX-060 can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE… Expand
    ConditionsLymphoma
    InterventionBiological
    A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma
    • 30
    • PDF
    A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
    • 220
    Dosing of a phase I study of KW-0761, an anti-CCR4 antibody, for adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
    • R. Suzuki
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2010
    • 17
    Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
    • 1,087
    • PDF
    A phase 1 dose‐escalation study of XmAb®2513 in patients with relapsed or refractory Hodgkin lymphoma
    • 8
    Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin
    • 24
    • PDF

    References

    SHOWING 1-10 OF 25 REFERENCES
    A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma.
    • R. Schnell, O. Staak, +8 authors A. Engert
    • Medicine
    • Clinical cancer research : an official journal of the American Association for Cancer Research
    • 2002
    • 130
    Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody.
    • R. Schnell, M. Dietlein, +10 authors A. Engert
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2005
    • 104